G6PC Genotype

Between meals, your liver and kidneys quietly release sugar into your bloodstream to keep you fueled. The G6PC (glucose-6-phosphatase catalytic subunit) gene carries the blueprint for the enzyme that performs the final step of that release. When both copies of this gene carry disease-causing changes, that release fails, and the consequences ripple through almost every organ system.

This test reads your G6PC sequence to identify whether you carry variants linked to glycogen storage disease type Ia (GSD Ia), a rare inherited condition. Knowing your status matters for family planning, for understanding unexplained low blood sugar or liver findings, and for confirming a clinical suspicion with a definitive genetic answer.

What G6PC Actually Does

The G6PC gene tells your cells how to build an enzyme called glucose-6-phosphatase. This enzyme sits in the membrane of a compartment inside your cells that processes and transports proteins and helps make fats (the endoplasmic reticulum) and performs the last chemical step that converts stored sugar into the free glucose your blood can carry. It is most active in your liver and kidneys, with smaller amounts in your intestine.

Without working glucose-6-phosphatase, your body cannot finish making sugar from stored glycogen or from raw materials like amino acids. Sugar gets stuck inside cells, glycogen and fat pile up in the liver and kidneys, and blood sugar drops dangerously low during fasting.

Glycogen Storage Disease Type Ia

Two damaged copies of G6PC cause GSD Ia, also called von Gierke disease. The hallmark is fasting low blood sugar, often paired with an enlarged liver, a buildup of lactic acid, high triglycerides, high cholesterol, and high uric acid. Symptoms usually appear in infancy or childhood, but milder variants can stay quiet for years.

In a Korean group of 54 GSD Ia patients, the c.648G>T variant was by far the most common change. Because that particular variant tends to cause only mild low blood sugar, many of those patients were not diagnosed until late, by which time they had already developed serious complications. A Japanese study of 32 patients carrying the same c.648G>T variant found that silent low blood sugar episodes became more frequent with age, even in people who felt well.

Long-term complications reported in human GSD Ia cohorts include benign liver tumors (hepatocellular adenomas), liver cancer, kidney disease, kidney stones, gout, growth delay, and bone thinning. In one cohort of 164 GSD Ia patients, 50 developed hepatocellular adenomas. Patients who developed adenomas had started uncooked cornstarch therapy at a much older age (median 14 years) than those who did not (median 3 years), an association that suggests earlier metabolic control may help postpone these tumors, though causation has not been proven.

Why Your Genotype Is Permanent but Still Worth Knowing

Your G6PC sequence is set at conception and does not change. That permanence is exactly why a single test is so useful: you only need to do it once, and the result informs every future decision about fasting tolerance, family planning, and monitoring for liver and kidney complications.

For asymptomatic relatives of someone with confirmed GSD Ia, testing can identify carriers (one copy) and at-risk individuals (two copies) before symptoms appear. Two carrier parents have a one-in-four chance of having a child with the full disease, which is why cascade testing within families changes reproductive planning.

Variant Frequencies Differ by Ancestry

GSD Ia variants are not evenly distributed across populations. Studies have documented different dominant variants in patients of Korean, Chinese, Pakistani, Iranian, Turkish, Italian, Tunisian, Hungarian, Czech/Slovak, French, and Indian ancestry. The c.247C>T (p.R83C) variant is the most common in Turkish GSD Ia patients, while c.648G>T dominates in East Asian populations. This matters because the variants a given lab tests for, and how it interprets borderline findings, depend on the panel's design and the reader's background.

One-Time Result

This is a once-in-a-lifetime test. The genotype itself does not need to be repeated unless the result is unexpected and a confirmatory method (such as Sanger sequencing after a panel call) is warranted. The ongoing tracking happens in the downstream measurements: blood glucose, lactate, triglycerides, uric acid, liver enzymes, and liver and kidney imaging. If you carry two damaged copies, those phenotype tests should be repeated on a schedule set with a metabolic specialist, often every few months in childhood and at least annually in adulthood.

When Results Can Be Misleading

Genetic results are usually clear-cut, but a few situations can muddy interpretation:

• Panel coverage limits: the assay only detects the specific variants it is designed to find. A negative result rules out the variants on the panel, not every possible change in G6PC. If clinical suspicion is high, full gene sequencing may be needed.
• Ancestry-specific variants: a variant common in one population can be rare or absent in another. A result interpreted against the wrong reference population may misjudge your actual risk.
• Variants of uncertain significance: sometimes the lab reports a change in G6PC whose clinical effect is not yet known. This is not a yes or no answer, and follow-up with a genetic counselor helps clarify what to do.
• Wrong gene, similar disease: GSD type Ib looks clinically similar but is caused by variants in the SLC37A4 (G6PT) gene, not G6PC. A G6PC-only test will miss GSD Ib.

Decision Pathway If You Test Positive

A positive result, especially two pathogenic variants, should trigger several next steps rather than just a repeat test. Consider:

• Confirm by a second method if the initial result came from a screening panel rather than full sequencing.
• Build a metabolic baseline: fasting glucose, lactate, triglycerides, total cholesterol, uric acid, liver enzymes, and a complete blood count, alongside abdominal imaging of the liver and kidneys.
• Involve specialists early: a metabolic geneticist or hepatologist for adults, and a pediatric metabolic specialist for children. A genetic counselor can help with family planning conversations.
• Talk to biological family members: siblings have a one-in-four chance of also being affected if both parents are carriers. Children of an affected adult will all be at least carriers.

For carriers (one variant), the disease itself does not develop, but reproductive partners may want to know their own status before having children.

A Note on Other Genes With Similar Names

G6PC is sometimes called G6PC1 to distinguish it from G6PC2 and G6PC3, which are different genes with different functions. G6PC2 variants have been linked to fasting glucose levels and type 2 diabetes risk in population studies, while G6PC3 variants cause a separate condition involving low neutrophil counts and immune problems. This test reads G6PC (G6PC1) only. If your concern is fasting glucose regulation or immune dysfunction, those conditions require their own targeted tests.